- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03647748
Effects of Green Light Therapy on Body Contouring and Cellulite (Cellulize)
August 23, 2018 updated by: Ward Photonics LLC
A double-blind, placebo-controlled randomized evaluation of the effect of Cellulize, a green light low level laser system for aesthetic use for the non-invasive reduction in fat layer for body contouring and reduction of cellulite.
Study Overview
Detailed Description
This clinical trial will provide objective evidence showing effectiveness of the Cellulize 532nm green light therapy for the non-invasive reduction in fat layer for body contouring, and for the non-invasive treatment for the appearance of cellulite.
Study Type
Interventional
Enrollment (Actual)
52
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Cape Coral, Florida, United States, 33904
- Wunderlich Chiropractic Clinic
-
Cocoa Beach, Florida, United States, 32931
- Mobile Laser Slimming
-
Lake Mary, Florida, United States, 32714
- Lake Mary Health and Wellness
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48104
- Michigan Center for Cosmetic Surgery, Ann Arbor, Michigan
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
14 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Study participant between the ages of 18 and older.
- Female only
- Subject is willing and able to abstain from partaking in any treatment other than the study procedures (existing or new) to promote body contouring/circumference reduction/weight loss during the course of study participation.
- Subject is willing and able to maintain his or her regular (typical pre-study) diet and exercise regimen without effecting significant change in either direction during study participation.
Exclusion Criteria:
- No photo-therapy (red or green) within 3 weeks of treatment.
- Known cardiovascular disease such as cardiac arrhythmias, congestive heart failure.
- Cardiac surgeries such as cardiac bypass, heart transplant surgery, pacemakers.
- Prior surgical intervention for body sculpting/weight loss, such as liposuction, abdominoplasty, stomach stapling, lap band surgery, etc.
- Medical, physical, or other contraindications for body sculpting/weight loss.
- Current use of medication(s) known to affect weight levels/cause bloating or swelling and for which abstinence during the course of study participation is not safe or medically prudent.
- Any medical condition known to affect weight levels and/or to cause bloating or swelling.
- Active infection, open wound (e.g. sores, cuts, ulcers, burns, etc.) or other external trauma to the areas to be treated with the laser/lymphatic drainage system devices.
- Photosensitive condition or medication.
- Active cancer within the past year.
- Pregnant, possibly pregnant or planning pregnancy prior to the end of study participation.
- Diminished ability to void waste (liver or kidneys).
- Developmental disability or cognitive impairment that in the opinion of the investigator would preclude adequate comprehension of the informed consent form and/or ability to record the necessary study measurements.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: Cellulize 532nm
Cellulize device using 532nm Green Light.
|
|
|
Sham Comparator: Cellulize Placebo (Sham Comparator)
Cellulize modified to appear as if it is running, but does not use the 532nm light. "Sham" Device, or "Placebo." |
A modified device utilizing a pigtail connector to bypass active treatment.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Average Change in Inches of Total Circumference Measurements
Time Frame: 2 weeks
|
Average Change in Inches of Total Circumference Measurements for effect of Cellulize, a LED 532nm green light low level laser system for aesthetic use for the non-invasive reduction in fat layer for body contouring from baseline measurements, and after treatment.
|
2 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Durability of Effect
Time Frame: 2 weeks
|
Durability of Effect: a term used to indicate whether the results of the primary outcome endure at the 2 week follow up time point.
If the average change in inches of total circumference continues decreasing or stays the same, then the durability of effect is assumed to endure for at least two weeks.
If the measurements at the 2-week time point show that the changes in inches return to previous measures at the start of treatment, then the effect is considered temporary.
|
2 weeks
|
|
Change in appearance of cellulite
Time Frame: 2 weeks
|
Change in appearance of cellulite is a measure of the Nurnberger-Muller Scale (NMS) from baseline to 2 weeks post-assessment for both of the right and left thighs.
|
2 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Robert H Burke, MD, Michigan Center for Cosmetic Surgery, Ann Arbor, Michigan
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2017
Primary Completion (Actual)
August 1, 2018
Study Completion (Actual)
August 1, 2018
Study Registration Dates
First Submitted
August 20, 2018
First Submitted That Met QC Criteria
August 23, 2018
First Posted (Actual)
August 27, 2018
Study Record Updates
Last Update Posted (Actual)
August 27, 2018
Last Update Submitted That Met QC Criteria
August 23, 2018
Last Verified
August 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CP16-02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fat Reduction
-
Zeltiq AestheticsCompleted
-
Goldman, Butterwick, Fitzpatrick and GroffAllerganCompletedFat ReductionUnited States
-
University of BaghdadEman Hammad HafithCompleted
-
Zeltiq AestheticsCompleted
-
AllerganCompletedNon-invasive Fat ReductionAustralia, Canada, Singapore, United Kingdom
-
Zeltiq AestheticsCompletedFat Reduction in the AbdomenCanada
-
AbbVieActive, not recruitingNon-Surgical Fat ReductionUnited States
-
AllerganCompletedNon-invasive Fat ReductionUnited States, France, Singapore, Sweden, Germany
-
Syneron MedicalUnknown
-
Zeltiq AestheticsCompletedFat Reduction in the Upper ArmCanada
Clinical Trials on Sham Comparator
-
Stanford UniversityRecruitingTreatment Resistant Depression | Bipolar II Disorder, Most Recent Episode Major Depressive | Current Depressive EpisodeUnited States
-
Case Western Reserve UniversityHighland Instruments, Inc.Recruiting
-
SanofiRecruitingGeographic AtrophyUnited States, Australia
-
Hong Kong Metropolitan UniversityHospital Authority, Hong KongRecruitingConstipation | Constipation Drug Induced | Psychiatric Drug Induced ConstipationHong Kong
-
NGM Biopharmaceuticals, IncCompletedGeographic AtrophyUnited States
-
Novartis PharmaceuticalsCompletedDiabetic Macular Edema | Macular Edema | Neovascular Age-related Macular Degeneration | Retinal Vein OcclusionsPuerto Rico, United States
-
Guang'anmen Hospital of China Academy of Chinese...Not yet recruitingLung Cancer
-
Fujian Medical University Union HospitalNot yet recruitingInsomnia Chronic | Subjective Cognitive Decline (SCD)
-
Universidade Federal FluminenseActive, not recruiting
-
Second Affiliated Hospital, School of Medicine,...Ningbo Medical Center Lihuili Hospital; First Affiliated Hospital of Zhejiang... and other collaboratorsActive, not recruitingDepressive Symptoms in Patients with EpilepsyChina